Exchange: NASDAQ Sector: Healthcare Industry: Medical Care Facilities
Current Signal: BUY (auto-tracking)
-12.42% $8.32
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 515.37 mill |
EPS: | -2.32 |
P/E: | -3.59 |
Earnings Date: | May 05, 2024 |
SharesOutstanding: | 61.94 mill |
Avg Daily Volume: | 0.677 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.59 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.13x |
Company: PE -3.59 | industry: PE 28.38 |
DISCOUNTED CASH FLOW VALUE |
---|
$3.68 (-55.82%) $-4.64 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 7.32 - 9.32 ( +/- 12.07%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Goldsmith George Jay | Sell | 15 740 | Ordinary Shares |
2024-03-12 | Goldsmith George Jay | Sell | 15 740 | Ordinary Shares |
2024-03-13 | Goldsmith George Jay | Sell | 17 203 | Ordinary Shares |
2024-03-13 | Goldsmith George Jay | Sell | 17 203 | Ordinary Shares |
2024-03-12 | Malievskaia Ekaterina | Sell | 15 740 | Ordinary Shares |
INSIDER POWER |
---|
2.11 |
Last 98 transactions |
Buy: 1 015 261 | Sell: 919 161 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $8.32 (-12.42% ) |
Volume | 3.56 mill |
Avg. Vol. | 0.677 mill |
% of Avg. Vol | 525.89 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $10.99 | N/A | Active |
---|
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.